Anti-viral therapy of chronic hepatitis C

( views:, downloads: )
SI Chong-wen()
Journal Title:
Volume 1, Issue 02, 2008
Key Word:


  • [1]Manns MP,McHutchison JG,Gordon SC,et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet,2001,358(9286):958-965.
  • [2]Hadziyannis SJ,Sene H Jr,Morgan TR,et al.Pegintefferonalpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration.and ribavirin dose.Ann Intern Med,2004,140(5):346-355.
  • [3]Ferrenci P,Fried MW,Shiffman ML,et al.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.J Hepatol,2005,43 (3):425-433.
  • [4]Davis GL,Wong JB,McHutchison JG,et al.Early virologic response to treatment with pegintederon alfa-2b plus rihavirin in patients with chronic hepatitis C.Hepatology,2003,38(3):645-652.
  • [5]Strader DS,Wright T,Thomas DL,et al.AASLD practice guideline:diagnosis,managemani,and treatment of hepatitis C.Hepatology,2004,39(4):1147-1171.
  • [6]Sethi A,Shiffman ML.Approach to the management of patients who failed to achieve sustained virologic response.Clin Liver Dis,2005,9(3):453-471.
  • [7]Anand BS,Currie S,Dieperink E,et al.Alcohol use and treatment of hepatitis C vires:results of a national muhicentor study.Gastroenterology,2006,130(6):1607-1616,
  • [8]Chung RT,Andersen J,Volberding P,et al.Pegiaterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.N Engl J Med,2004,351 (5):451-459.
  • [9]Patton HM,Patel K,Behling C,et al.The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.J Hepatol,2004,40(3):484-490.
  • [10]Fartoux L,Poujol-Robert A,Gu chat J,et al.Insulin resistance is a cause of steatnsis and fibrosis progression in chronic hepatitis C.Gut,2005,54(7):1003-1008.
  • [11]Sim R,Lecube A,Genesc J,et al.Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.Diabetes Care,2006,29(11):2462-2466.
  • [12]Yee HS,Currie SL,Darling JM,et al.Management and treatment of hepatitis C viral infection:recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.Am J Gaatroenterol,2006,101 (10):2360-2378.
  • [13]Bacon B,Regev A,Ghalib R,et al.Use of daily interferon alfacon-1 (integren,CIFN) plus ribavirin in patients infected with hepatitis C who are nonresponders to previous pegylated interferon plus RBV therapy:24-week data from the DIRECT trial.Hepatology,2006,44(4,Suppl 1):698A.
  • [14]Afdhal NH,Freilieh B,Levine R,et al.Colchicine versus PEGlntron long-term (COPILOT) trial:interim analysis of clinical outcomes at year 2.Hepatology,2004,40(Suppl 1):238A.
  • [15]Lee WM,Dienstag JL,Lindsay KL,et al.Evolution of the HALT-C trial:pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespanders.Contr Clin Trials,2004,25(5):472-492.
  • [16]Forestier N,Reesink HW,Weegink CJ,et al.Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.Hepatology,2007,46 (3):640-648.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615